RTP Mobile Logo
Prostate Cancer Update Think Tank Companion CME Activity – Video Module VI: Chemotherapy
Released February 2011

Dr A Oliver Sartor discusses the efficacy and current placement of first-line docetaxel-based chemotherapy and provides an introduction to the use of cabazitaxel for castration-resistant prostate cancer.

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, urologists and radiation oncologists.


    • Educate patients with castration-resistant prostate cancer (CRPC) about the efficacy of docetaxel-based chemotherapy and its current placement as first-line chemotherapy in evidence-based prostate cancer treatment algorithms.
    • Compare and contrast the efficacy and safety of cabazitaxel with existing therapeutic strategies for patients with CRPC previously exposed to docetaxel.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains a video component and downloadable slides. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    A Oliver Sartor, MD
    Medical Director, Tulane Cancer Center
    Piltz Endowed Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Bristol-Myers Squibb Company, GlaxoSmithKline; Consulting Agreements: Algeta ASA, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Corporation, GlaxoSmithKline, GPC Biotech, Johnson & Johnson Pharmaceuticals, Medivation, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis; Paid Research: Algeta ASA, AstraZeneca Pharmaceuticals LP, Cougar Biotechnology Inc, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Sanofi-Aventis; Speakers Bureau: EUSA Pharma.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Dendreon Corporation, Millennium Pharmaceuticals Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2011
    Expiration date: February 2012

Acknowledge and close

Watch video
(WIFI is recommended for best performance):